ALACHUA, Fla.–(BUSINESS WIRE)–RTI Biologics Inc. (RTI) (Nasdaq: RTIX), the Florida-based processor of orthopedic, dental, surgical specialties and other biologic implants, is launching two new biologic implants for use in sports medicine surgeries at the American Academy of Orthopaedic Surgeons (AAOS) annual meeting in New Orleans this week. BTB Select®, an innovative allograft that provides precision sized tendons for ACL reconstruction, and BioCAP Select™, a composite allograft plug for customized bone void filling, will be introduced at the RTI Biologics exhibit during the AAOS meeting.
“The BTB Select is an exciting allograft solution that addresses an overall market shift toward shorter BTBs, which are more difficult to recover naturally”
The next-generation BTB Select is an innovative solution that allows for precision sized matching relative to the intra-articular length of BTB allografts. The BTB Select is sterilized through RTI’s BioCleanse® process, which inactivates or removes potential pathogens from tissue using a specific formula while maintaining the tissue’s biomechanical properties.
“The BTB Select is an exciting allograft solution that addresses an overall market shift toward shorter BTBs, which are more difficult to recover naturally,” said Roger Rose, executive vice president for RTI Biologics. “This innovative product addresses a significant clinical need and ensures that we maximize every gift of donation received.”
Precision sized BTB intra-articular length is accomplished by utilizing an assembled cortical bone block in conjunction with an Achilles tendon, both derived from a single donor. The assembled cortical block features a proprietary anti-slip design, and the natural bone block allows for multiple fixation types.
“This new generation of assembled products provides significant processing advantages over previous designs and allows for reproducible machining and assembly,” Rose said. “These were two challenges faced in earlier designs, and we are pleased with the advancements made that enable us to produce a BTB allograft solution that meets our high quality and safety standards.”
The BioCAP Select serves to broaden the sports medicine portfolio and marks RTI’s entry into the specialized area of Osteochondral Autograft Transfer System (OATS), a common procedure to treat small cartilage lesions.
The BioCAP Select is an innovative, fully biological bone void filler, and for the surgeon, this allograft provides a reliable solution to address voids created by OATS, which may lead to pain and/or discomfort for the patient if left empty.
RTI’s products are sterilized through processes validated by tissue type. The BioCAP Select implant is an assembled graft, derived from a single donor; the demineralized cortical cap is sterilized through the Cancelle™ SP DBM Sterilization Process, and the cancellous plug is sterilized through the BioCleanse® Tissue Sterilization Process.
The BTB Select is commercially available, while the BioCAP Select will be available through a limited launch following the AAOS meeting. Information and representative models for both BioCAP Select and BTB Select will be available at the AAOS meeting, booth #2967. For further information, contact an RTI representative at (800) 624-7238.
About RTI Biologics Inc.
RTI Biologics Inc. is a leading provider of sterile biological implants for surgeries around the world with a commitment to advancing science, safety and innovation. RTI prepares human donated tissue and bovine tissue for transplantation through extensive testing and screening, precision shaping and proprietary, validated sterilization processes. These allograft and xenograft implants are used in orthopedic, dental, hernia and other specialty surgeries.
RTI’s innovations continuously raise the bar of science and safety for biologics – from being the first company to offer precision-tooled bone implants and assembled technology to maximize each gift of donation, to inventing validated sterilization processes that include viral inactivation steps. Two such processes – the BioCleanse® Tissue Sterilization Processand the Tutoplast® Tissue Sterilization Process – have a combined record of more than two million implants distributed with zero incidence of allograft-associated infection. These processes have been validated by tissue type to penetrate tissue, inactivate or remove viruses and a wide range of organisms using worst-case testing and maintain tissue biocompatibility and functionality.
RTI’s worldwide corporate headquarters are located in Alachua, Fla., with international locations in Neunkirchen, Germany, and Aix-en-Provence, France. The company is accredited in the U.S. by the American Association of Tissue Banks.
Forward Looking Statement
This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations, estimates and projections about our industry, our management’s beliefs and certain assumptions made by our management. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” variations of such words and similar expressions are intended to identify such forward-looking statements. In addition, except for historical information, any statements made in this communication about anticipated financial results, growth rates, new product introductions, future operational improvements and results or regulatory approvals or changes to agreements with distributors also are forward-looking statements. These statements are not guarantees of future performance and are subject to risks and uncertainties, including the risks described in public filings with the U.S. Securities and Exchange Commission (SEC). Our actual results may differ materially from the anticipated results reflected in these forward-looking statements. Copies of the company’s SEC filings may be obtained by contacting the company or the SEC or by visiting RTI’s Web site at www.rtix.com or the SEC’s Web site at www.sec.gov.